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A B S T R A C T
The aim of this study is to investigate the pharmacokinetics of 5′-valyl-cytarabine hydro-
chloride (OPC) when co-administered with cephalexin, which are both the substrates of PepT1.
The drugs were administered orally by gavage. Blood samples were collected from the orbital
plexus of the rats after oral administration of drug solutions. A new high-performance liquid
chromatographic method was validated and used for determination of the two drugs. Phar-
macokinetic parameters were calculated using DAS 2.1.1 software with noncompartmental
analysis. After oral administration of OPC and co-administration of OPC and cephalexin,
there were significant differences in the main pharmacokinetic parameters.The main phar-
macokinetic parameters for the OPC group and the co-administrative group were as follows:
AUC0-10 (18,168.7 ± 2561.4) ng·h/ml and (13,448.5 ± 2544.73) ng·h/ml, AUC0-∞ (18,683.1 ± 3066.5)
ng·h/ml and (13,721.1 ± 2683.0) ng·h/ml, Cmax (6654.8 ± 481.3) ng/ml and (4765.1 ± 928.9) ng/
ml, respectively. The results showed that the bioavailability of OPC could be reduced when
co-administered with cephalexin, suggesting that the efficacy of a novel drugmight be reduced
when it came to combination use of β-lactam antibiotics.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Drug transporters are very important in the process of oral drug
absorption, distribution,metabolism, and elimination.Twomajor
uptake transporters are two solute carrier (SLC and SLCO) su-
perfamilies [1]. There are two kinds of POT having transport
activity. One is PepT1, which is mainly expressed in the small
intestine and also in the proximal tubules of the kidney [2,3].
The other is PepT2, which is predominantly located in the
kidney [4]. Cytarabine (1-β-D-arabinofuranosylcytosine) is used
in approximately 70% of cases of acute myelogenous leuke-
mia (AML) [5]. Combination using of cytarabine and interferon-
alpha shows great efficiency in the treatment of chronic myeloid
leukemia (CML) [6]. Cytarabine is also an alternative drug to
many cancers (stomach cancer, pancreatic cancer, liver cancer,
colon cancer, lung cancer, breast cancer, uterine cancer, etc.).
It has a quite short half-life which necessitates the adminis-
trative way of continuous infusion to maintain therapeutic
plasma level, which is not convenient and time-consuming.
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5′-Valyl-cytarabine hydrochloride (see Fig. 1) is a novel 5′-
amino acid ester prodrug of cytarabine. It is the substrate of
PepT1, which increases the oral bioavailability of cytarabine.
An in vivo pharmacokinetics study showed that the oral ab-
solute bioavailability of rats increased 40% compared with that
of cytarabine. Cytarabine could be released from the prodrug
rapidly [7].This improvement suggested that OPCmight become
a promising oral drug in dealing with AML, CML and stomach
cancer, etc. A number of drugs have been reported as the sub-
strates of PepT1, including β-lactam antibiotics, ACE-inhibitors,
renin inhibitors, thrombin inhibitors, bestatin and prodrugs of
acyclovir and ganciclovir [8–15].
Cytarabine is mainly used in the treatment of acute my-
elogenous leukemia and non-Hodgkin’s lymphoma. It is also
used with other chemotherapy agents when people suffered
chronic myelogenous leukemia, multiple myeloma, Hodg-
kin’s lymphoma and non-Hodgkin’s lymphoma [16].Therefore,
cytarabine plays an important role in cancer chemotherapy.
Patients are susceptible to infections due to a compromised
immune system resulting from chemotherapy. Neutropenia and
fever are very common life-threatening complications in cancer
chemotherapy patients. Oral antibiotics can be an alternative
approach for low risk cancer patients. To date, the best oral
regimen is a combination of quinolone and amoxicillin/
clavulanate [17]. Cephalexin is a kind of broad-spectrum, oral,
antimicrobial agent. Cephalexin and amoxicillin are both
β-lactam antibiotics, they share similar functional groups. Pre-
viously, the pharmacokinetic interaction between cephalexin
and quinapril – a substrate of PepT1 – was investigated; the
pharmacokinetic interaction between cephalexin and JBP485
– another substrate of PepT1 – was also studied. Cephalexin
was chosen as a typical kind of β-lactam antibiotic for the study
of the interaction between substrates of PepT1 [18,19].
Previously, the study of the absorption of OPC in the pres-
ence of cephalexin by using a single pass perfusion model was
completed in our laboratory. The results showed that the ab-
sorption of OPC was greatly inhibited by cephalexin. However,
the intraluminal environment is quite complicated and there
are many differences between in vivo experiments and in situ
single pass perfusion. Further study has to be carried out to
elucidate the pharmacokinetic interaction in rats between
OPC and cephalexin which are both substrates of PepT1.
Pharmacokinetic interaction between the two drugs is of great
importance to the clinical application of OPC.
2. Materials and methods
2.1. Materials
OPC was provided by Kunming Jida Pharmaceutical Co., Ltd.
(Kunming, China) with a purity of 99.8%. Cytarabine was pur-
chased from Langrb Technology Co., Ltd. (Beijing, China), with
a purity of 99.9%. Cephalexin with a purity of 98% was pur-
chased fromHMC ChemicalTechnology Co., Ltd. (Beijing, China).
Lamivudine with a purity of 99.7% was purchased from Longze
Pharmaceutical Co., Ltd. (Shijiazhuang, China).Tetrahydrouridine
was provided by Toronto Research Chemicals Inc. The rest of
the chemicals were of analytical grade.
Male Sprague–Dawley (SD) rats weighing 220–250 g were pur-
chased from the Experimental Animal Center (Shenyang
Pharmaceutical University, Shenyang, China). The experimen-
tal protocol was evaluated and approved by the University Ethics
Committee for the use of experimental animals and con-
formed to the Guide for Care and Use of Laboratory Animals.
2.2. Preparation of solutions for oral administration
The cephalexin solution was prepared by dissolving 125 mg
cephalexin in 25 ml aqueous solution to obtain a concentra-
tion of 5 mg/ml. The OPC solution was prepared by dissolving
64 mg OPC in 25 ml aqueous solution to obtain a concentra-
tion of 1.5 mg/ml (calculated as cytarabine).The mixed solution
of cephalexin and OPC was prepared by dissolving 125 mg
cephalexin and 64 mg OPC in 25 ml aqueous solution.
2.3. Preparation of standard solution
Standard solutions of the two drugs at concentrations of 0.05,
0.1, 0.2, 0.25, 0.5, 1.0, 5.0, 8.0, 10.0 μg/ml for cytarabine and 0.2,
0.4, 0.8, 1.0, 2.0, 4.0, 20.0, 32.0, 40.0 μg/ml for cephalexin were
prepared.The internal standard solution was prepared by dis-
solving 30 mg lamivudine in 100 ml distilled water to obtain
a stock solution. 1 ml stock solution was diluted with water
to obtain 100 ml solution at a concentration of 3 μg/ml.
2.4. Collection and treatment of biological samples
Serial blood samples (0.5 ml) were obtained from the orbital
plexus at 5, 15, 30, 45 min, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 h after oral
administration separately. The blood samples were centri-
fuged at 13,000 r/m for 10 min, plasma was then removed and
stored at −80 °C until later analysis. During sampling, rats
were anesthetized with ether. All samples were placed into
heparinized tubes containing the deaminase inhibitor,
tetrahydrouridine (0.1 mM). A 100 μl aliquot of internal stan-
dard solution and a 100 μl aliquot of distilled water were added
to a 100 μl aliquot of plasma and vortex-mixed for 3 min.Then,
a 0.8 ml aliquot of acetonitrile was added, vortex-mixed for
3 min, centrifuged at 13,000 r/m for 10 min, then the super-
natant was transferred to a clean tube and dried under nitrogen
Fig. 1 – Structure of 5′-valyl-cytarabine hydrochloride.
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gas at 37 °C.The residue was dissolved in 100 μl distilled water,
centrifuged for 10 min at 13,000 r/m, and 20 μl supernatant was
injected into the HPLC column.The peak-area ratios of the bio-
logical sample to the internal standard were used to calculate
drug concentrations at different time points.
2.5. Chromatographic conditions
HPLC analysis was carried out on aWaters liquid chromatog-
raphy instrument equipped with a Waters 2489 UV/Visible
Detector and e2695 Separations Module.A C18 column (ZORBAX
SB-C18, 4.6 mm × 250 mm, 5 μm,AgilentTechnologies) was used;
HPLC elution was carried out using phosphate buffer contain-
ing 0.005 M K2HPO4 and KH2PO4 and methanol. The elution
gradients are listed in Table 1. Column temperature was 30 °C,
flow rate was 1.0 ml/min, ultraviolet detection wavelength was
254 nm and injection volume was 20 μl.
2.6. Methodology verification
2.6.1. Method specificity
Under the chromatographic conditions described, there was
no interference from the endogenous substances present in
the plasma.
2.6.2. Preparation of standard curves and quality control
samples
Different concentrations of standard solution were mixed with
100 μl aliquots of blank plasma to prepare biological sample
solutions.The regression equation was obtained from the plot
of the peak-area ratio of cephalexin or cytarabine to internal
standard (As/Ai) as the Y-axis and the concentrations (C) as the
X-axis. Cytarabine (0.1, 0.5, 8.0 μg/ml) and cephalexin (0.4, 2.0,
32 μg/ml) were added in blank plasma to prepare the low,
medium and high levels of quality control (QC) samples. The
spiked samples were then treated as the sample preparation
procedure indicated in Section 2.4.
2.6.3. Extraction recovery
The extraction efficiency was determined by comparing the
peak areas of extracted QC samples with peak areas of the stan-
dard solution and IS solution added to the blank plasma extract.
The concentration of the IS solution was 3 μg/ml. Three con-
centration levels (0.1, 0.5, 8.0 μg/ml for cytarabine and 0.4, 2.0,
32 μg/ml for cephalexin) in rat plasma were studied in recov-
ery experiments.
2.6.4. Precision experiment
The intra-day precision and inter-day precision were deter-
mined at the same three high,medium and low concentrations
of QC samples. The intra-day precision was obtained from 6
replicates injected on the same day, while the inter-day pre-
cision was obtained from samples injected on 3 different days.
2.6.5. Lower limit of quantification (LLOQ)
The samples of LLOQ were made by using the method of pre-
paring the lowest point of the standard curve with standard
solution. The intra-day precision was obtained from 6 repli-
cates injected on the same day. The accuracy was calculated
by the mean deviation of all concentrations from the theo-
retical value.
2.6.6. Stability test
The stability of the plasma samples at the high, medium and
low concentrations were examined after storing at room tem-
perature for 12 h, after repeated freeze–thawing (3 times) and
after storing at −80 °C for 14 d.
2.7. Animal study
Before the experiments, SD rats were fasted for 12 h with free
access to water. They were then randomly divided into three
groups, namely, OPC group after an oral administration at
15 mg/kg (calculated as cytarabine), cephalexin group after an
oral administration at 50 mg/kg [18] cephalexin and combi-
nation group after an oral administration at 15mg/kg (calculated
as cytarabine) and 50 mg/kg cephalexin, with 6 rats per group.
The drugs were administered orally by gavage. 0.5 ml blood
samples were collected from the orbital plexus of the rats before
and after oral administration of drug solutions, at time inter-
vals of 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8 and 10 h. The
rats were then sacrificed. The concentration of drugs in each
sample was determined as described previously.
2.8. Pharmacokinetics and statistical analysis
The main pharmacokinetic parameters were calculated ac-
cording to the DAS 2.1.1 software with non-compartmental
analysis. The statistical differences were tested using Student
t test at the P < 0.05 level.
3. Results and discussion
During cancer chemotherapies, combination usage of cytarabine
with broad-spectrum antibiotics is very common. Drug–drug
pharmacokinetic interaction is of great importance in guiding
clinical use of drug dose. In this study, cephalexin’s influence
on the pharmacokinetics of OPC was investigated.
3.1. Methodology verification
3.1.1. Specificity of the analytical method
An example of a typical chromatogram is shown in Fig. 2. The
peak shapes were very good and the three compounds were
separated totally. Endogenous components in plasma did not
cause any interference in the chromatogram.
Table 1 – The elution gradients of HPLC analysis.
Time (min) Phosphate buffer (%) Methanol (%)
0 95 5
2 95 5
7 70 30
13 70 30
14 95 5
17 95 5
145a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 2 ( 2 0 1 7 ) 1 4 3 – 1 4 8
3.1.2. Standard curves
Using the internal standard method, the linear regression lines
of the standard concentration (C) versus the peak area ratio
(Y) were plotted, the linear range was 0.05–10 μg/ml for
cytarabine and 0.2–40 μg/ml for cephalexin.The regression equa-
tions of cytarabine and cephalexin in rat plasma are Y = 0.0002C–
0.0033, r = 0.9999 and Y = 0.0001C–0.0173, r = 0.9999.
3.1.3. Lower limit of quantification (LLOQ)
The LLOQ of cytarabine and cephalexin were 0.05 and 0.2 μg/ml,
the RSD of intra-day precision were 7.3% and 2.4%. The RE of
accuracy were −8.8% and −6.7% respectively.
3.1.4. Recovery, precision and stability results
The extraction recovery of each biological sample was more
than 90%, which is shown in Table 2. The results of the pre-
cision tests are shown in Table 3. The intra-day precision and
inter-day precision were less than 15%. After three freeze/
thaw cycles, all samples were found to be stable with an
accuracy of 15%.After sample preparation of nitrogen blowing,
the samples at ambient temperature for 12 h were stable with
an accuracy of 15% at three levels of QC samples. After 14 days
storage in −80 °C, all samples were stable with accuracy less
than 15%. The stability was good and the RSD was less than
5%. The results are shown in Table 4.
3.2. Pharmacokinetic study
Mean plasma concentration–time curves of cytarabine after oral
administration of OPC (dose 15 mg/kg calculated as cytarabine)
without and with cephalexin (dose 50 mg/kg) to SD rats
(mean ± SD, n = 6) are shown in Fig. 3. Cephalexin (dose 50 mg/
kg) after oral administration without and with OPC (dose 15 mg/
kg calculated as cytarabine) to SD rats (mean ± SD, n = 6) are
shown in Fig. 4.When the two drugs were administered orally
in combination, the oral bioavailability and maximum con-
centration of OPC were significantly decreased compared with
those for the control group. The area under the curve (AUC)
of OPC was only 74% of those of the control group, the AUCs
of the combination group (AUC0-t 13,448.5 ± 2544.7 ng·h/ml
and AUC0-∞ 13,721.1 ± 2683.0 ng·h/ml) were significantly
lower (P < 0.05) than OPC in the control group (AUC0-t
18,168.7 ± 2561.4 ng·h/ml and AUC0-∞ 18,683.1 ± 3066.5 ng·h/
ml).The Cmax of OPC was only 72% of those of the control group.
Fig. 2 – Typical chromatogram obtained from an extract of blank serum spiked with 1000 ng/ml cytarabine, 4000 ng/ml
cephalexin and the IS; cytarabine, cephalexin and IS were eluted at 5.223, 13.099 and 9.180 min, respectively.
Table 2 – Recovery for the analysis of cytarabine and
cephalexin in rat plasma (n = 3).
Recovery (%) Cytarabine (ng/ml) Cephalexin (ng/ml)
100 500 8,000 400 2,000 32,000
Mean (%) 94.6 100.4 92.9 93.2 96.2 95.6
SD (%) 3.4 3.1 0.2 3.0 0.3 0.1
RSD (%) 3.6 3.1 0.2 3.2 0.3 0.1
Table 3 – Precision and accuracy for the analysis of cytarabine and cephalexin in rat plasma (n = 6).
Analytes Added concentration (ng/ml) Found concentration (ng/ml) Intra-day RSD (%) Inter-day RSD (%) RE (%)
Cytarabine 100 95.6 4.0 13.4 −4.4
500 494.6 1.2 3.7 −1.1
8,000 7,962.0 0.6 1.6 −0.5
Cephalexin 400 375.5 4.0 5.0 −6.1
2,000 2,001.6 1.6 8.8 0.1
32,000 31,726.5 1.7 12.8 −0.9
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The Cmax of OPC (4765.1 ± 928.9 ng/ml) in the combination group
was found to be significantly lower than that in the control
group (6654.8 ± 481.3 ng/ml). tmax and t1/2 of OPC in the co-
administration group were 0.8 ± 0.2 h and 1.7 ± 0.7 h, whereas
OPC in the control group has tmax and t1/2 of 0.8 ± 0.1 h and
1.7 ± 0.8 h (Table 5). Cephalexin competed with OPC for the
active site of Pept1, limiting the extent of absorption of OPC.
The velocity of absorption was not changed remarkably, which
might be due to Pept1 being not saturated. Most of the drugs
were absorbed passively through oral administration. However,
substrates of Pept1 were transported actively by an energy-
dependent transporter. Pept1 with low affinity and high capacity
was mainly located in the intestine, its expression decreased
from the duodenum to the ileum. There were many sub-
strates of Pept1, β-lactam antibiotics, ACE-inhibitors, renin
inhibitors, thrombin inhibitors, bestatin and prodrugs of
acyclovir and ganciclovir. OPC and cephalexin were both sub-
strates of Pept1, they both had the same chemical structure
of peptide. AUCs and Cmax of cephalexin of the combination
group were also lower than those of cephalexin with single ad-
ministration. However, there were no significant differences
between the pharmacokinetic parameters of cephalexin without
and with interaction of OPC. Firstly, it was because of the high
dosage of cephalexin compared with the quite low dosage of
OPC. Secondly, cephalexin probably had higher affinity for Pept1
compared with OPC.
4. Conclusion
Decreased bioavailability of OPC was observed when co-
administered with cephalexin, which can reduce the novel drug
Table 4 – Stability of cytarabine and cephalexin in rat plasma under various storage conditions (n = 3).
Conditions Analytes Added Concentration (ng/ml) Found Concentration (ng/ml) SD (%) RSD (%) RE (%)
Three freeze/thaw cycles Cytarabine 100 97.5 3.5 3.5 −2.5
500 495.6 3.0 0.6 −0.9
8,000 7,852.4 12.0 0.2 −1.8
Cephalexin 400 392.6 6.6 1.7 −1.9
2,000 2,083.2 5.2 0.2 4.2
32,000 32,402.9 41.7 0.1 1.3
Room temperature for 12 h Cytarabine 100 97.4 4.2 4.3 −2.6
500 492.1 0.9 0.2 −1.6
8,000 7,927.6 7.4 0.1 −0.9
Cephalexin 400 394.5 7.2 1.8 −1.4
2,000 2,038.8 12.7 0.6 1.9
32,000 31,936.8 42.1 0.1 −0.2
Freezing for 14 d at −80 °C Cytarabine 100 86.8 0.6 0.6 −13.2
500 497.9 3.9 0.8 −0.4
8,000 8,000.2 8.7 0.1 0.0
Cephalexin 400 369.2 2.4 0.7 −7.7
2,000 1,952.7 10.8 0.6 −2.4
32,000 30,965.1 48.2 0.2 −3.2
Fig. 3 – Mean plasma concentration–time curves of
cytarabine after oral administration of OPC (dose 15 mg/kg
calculated as cytarabine) without and with cephalexin
(dose 50 mg/kg) to SD rats (mean ± SD, n = 6).
Fig. 4 – Mean plasma concentration–time curves of
cephalexin (dose 50 mg/kg) after oral administration
without and with OPC (dose 15 mg/kg calculated as
cytarabine) to SD rats (mean ± SD, n = 6).
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efficacy when it comes to clinical use.We should pay great at-
tention to the combination usage of OPC and β-lactam
antibiotics. Different dosages of OPC and β-lactam antibiotics
in humans still need further study.
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